Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.

Autores de IIS La Fe

• Jaime Sanz Caballer

  Autor

• Miguel Ángel Sanz Alonso

  Autor

Participantes ajenos a IIS La Fe

• Labopin, Myriam
• Aljurf, Mahmoud
• Sousa, Aida Botelho
• Craddock, Charles
• Zuckerman, Tsila
• Labussiere-Wallet, Helene
• Campos, Antonio
• Grillo, Giovanni
• Ozkurt, Zubeyde Nur
• Cornelissen, J J
• Remenyi, Peter
• Martino, Massimo
• Porras, Rocio Parody
• Nagler, Arnon
• Gorin, Norbert-Claude
• Mohty, Mohamad
• Acute Leukemia Working Party of the European Society for Blood and
• Marrow Transplantation (EBMT)

Grupos

• Hematología y Hemoterapia

Abstract

We retrospectively compared outcomes of a large series of adult patients with APL in CR2 receiving alloHSCT (n = 228) or autoHSCT (n = 341) reported to the European Society for Blood and Marrow Transplantation from January 2004 to December 2018. The 2-year cumulative incidence of non-relapse mortality was significantly higher for alloHSCT 17.3% (95% CI 12.5-22.8) compared with autoHSCT 2.7% (95% CI 1.2-5) (p = 0.001), while differences in relapse rate were not significant (28% versus 22.9%; p = 0.28). Leukemia-free survival (LFS) and overall survival (OS) favored autoHSCT with 74.5% (95% CI 69-79.2) and 82.4% (95% CI 77.3-86.5) compared with alloHSCT with 54.7% (95% CI 47.5-61.3) (p = 0.001) and 64.3% (95% CI 57.2-70.6), respectively (p = 0.001 and p = 0.001). Multivariable analysis showed significantly worse LFS after alloHSCT (HR 0.49; 95% CI 0.37-0.67; p < 0.0001), older age (p = 0.001), and shorter time from diagnosis to transplant (p = 0.00015). Similar results were obtained for OS. The study shows that autoHSCT resulted in better survival outcomes (LFS and OS) for APL in CR2. These results were mainly due to reduced NRM in the autoHSCT as compared to alloHSCT.